A ready-made vaccine taught 99% of pancreatic-cancer patients' immune systems to hunt

Pancreatic cancer's engine is usually a broken gene called KRAS — and unlike personalised vaccines, an off-the-shelf vaccine can target its most common mutations straight from the shelf. In the Phase 2 AMPLIFY-7P trial, published in Nature Medicine and led by Mayo Clinic's Ben George, 89 of 90 evaluable vaccinated patients developed immune responses aimed at those mutations, and 95.5% still had them nearly a year later. Honesty matters: the trial did not prove patients lived longer without recurrence, and a Phase 3 trial is planned. But teaching almost every patient's immune system to recognise pancreatic cancer at all is a door that was closed before.

SDG 3 · Good health and well-being — Mechanism: tech innovation